CN113999410B - 一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法 - Google Patents
一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法 Download PDFInfo
- Publication number
- CN113999410B CN113999410B CN202111065439.9A CN202111065439A CN113999410B CN 113999410 B CN113999410 B CN 113999410B CN 202111065439 A CN202111065439 A CN 202111065439A CN 113999410 B CN113999410 B CN 113999410B
- Authority
- CN
- China
- Prior art keywords
- solution
- collagen
- double
- hydrogel
- burn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 67
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 48
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 102000008186 Collagen Human genes 0.000 claims abstract description 40
- 108010035532 Collagen Proteins 0.000 claims abstract description 40
- 229920001436 collagen Polymers 0.000 claims abstract description 40
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229920002413 Polyhexanide Polymers 0.000 claims abstract description 37
- 239000002105 nanoparticle Substances 0.000 claims abstract description 33
- 239000013154 zeolitic imidazolate framework-8 Substances 0.000 claims abstract description 33
- MFLKDEMTKSVIBK-UHFFFAOYSA-N zinc;2-methylimidazol-3-ide Chemical compound [Zn+2].CC1=NC=C[N-]1.CC1=NC=C[N-]1 MFLKDEMTKSVIBK-UHFFFAOYSA-N 0.000 claims abstract description 33
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000661 sodium alginate Substances 0.000 claims abstract description 16
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 16
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 16
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 230000037314 wound repair Effects 0.000 claims abstract description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 59
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 17
- 239000012498 ultrapure water Substances 0.000 claims description 17
- 238000000502 dialysis Methods 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 13
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000007853 buffer solution Substances 0.000 claims description 9
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 239000012452 mother liquor Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract description 4
- 230000010261 cell growth Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 22
- 206010052428 Wound Diseases 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- HCWOVPZEAFLXPL-UHFFFAOYSA-N diphenyl propanedioate Chemical compound C=1C=CC=CC=1OC(=O)CC(=O)OC1=CC=CC=C1 HCWOVPZEAFLXPL-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- XIOUDVJTOYVRTB-UHFFFAOYSA-N 1-(1-adamantyl)-3-aminothiourea Chemical compound C1C(C2)CC3CC2CC1(NC(=S)NN)C3 XIOUDVJTOYVRTB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N dihydroxy-phenylborane Natural products OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- UTHULKKJYXJZLV-UHFFFAOYSA-N (3-aminophenoxy)boronic acid Chemical compound NC1=CC=CC(OB(O)O)=C1 UTHULKKJYXJZLV-UHFFFAOYSA-N 0.000 description 1
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2479/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2461/00 - C08J2477/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2487/00—Characterised by the use of unspecified macromolecular compounds, obtained otherwise than by polymerisation reactions only involving unsaturated carbon-to-carbon bonds
Abstract
本发明公开了一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,具体为:首先制备负载聚六亚甲基双胍的ZIF‑8纳米粒子,将3‑氨基苯硼酸接枝到类人胶原蛋白上得到改性的类人胶原蛋白,利用EDC和NHS活化海藻酸钠,最后利用海藻酸钠与ZIF‑8纳米粒子及改性的类人胶原蛋白复合交联,形成具有稳定空间结构的双网络水凝胶,经过Co60照射灭菌即获得烧烫伤创面修复的双交联抗菌水凝胶。本发明制备方法简单易行,重现性好,制备的双交联抗菌水凝胶兼具长效缓释抗菌能力和良好的促上皮细胞生长能力,在烧烫伤创面修复方面具有理想的性能,应用前景广阔。
Description
技术领域
本发明涉及一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,属于生物医用材料技术领域。
背景技术
烧烫伤是最具破坏性的皮肤创伤之一,每年造成超过18万人死亡。感染也是烧伤发病率和死亡率的主要原因之一,病原体可以在最初的48小时内定居在伤口表面,其中院内伤口感染率约为31%。烧烫伤是以皮肤结构和功能受损为主要表现的损伤,与其他创伤相比,创伤面积更大、更不规则和严重出血的烧伤更容易感染且愈合缓慢。其治疗的核心内容为有效控制创面感染,提供有益愈合的微环境,以此来加速细胞修复及再生进程。因此,早期控制感染和促上皮细胞生长是治愈烧烫伤皮肤损伤的有效手段。
针对目前烧烫伤医用敷料而言,基本都是着眼于皮肤组织的修复,对于烧烫伤创面进行抗菌处理则采取另外用药的方式,这种处理方式会造成创面局部短期内毒性过大,增加创面组织细胞负担,不利于创面组织修复。查阅资料显示鲜见同时兼具长效抗菌能力和良好的皮肤组织修复能力的水凝胶敷料。如果能开发一种允许持续或较慢时间依赖性受控释放的给药平台无疑可以有效抑菌协同促组织细胞生长修复,大大提高治疗效果。
发明内容
本发明针对上述现有技术的不足,提供了一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法。
本发明实现过程如下:
一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,包括如下步骤:
(1)负载聚六亚甲基双胍的ZIF-8纳米粒子的制备
将聚六亚甲基双胍和2-甲基咪唑溶解于甲醇中,向其中加入硝酸锌,室温充分反应后离心收集沉淀,用乙醇洗涤、干燥获得负载聚六亚甲基双胍的ZIF-8纳米粒子;
(2)改性的类人胶原蛋白(HLC)的制备
将类人胶原蛋白溶解于中性PBS缓冲液中,向其中加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和N-羟基琥珀酰亚胺(NHS),再加入3-氨基苯硼酸半硫酸盐(APBA),调节溶液pH为4~5并进行充分搅拌,将混合液置于透析袋(透析袋截留分子量为3500)进行透析2-5天,收集透析母液并冷冻干燥获得改性的类人胶原蛋白;
(3)双交联抗菌水凝胶的制备
将负载聚六亚甲基双胍的ZIF-8纳米粒子溶于超纯水中制成A液,将改性的类人胶原蛋白溶于中性PBS缓冲液中制成B液,将海藻酸钠溶解于超纯水中,向其中加入EDC和NHS并搅拌溶解制成C液;将A液、B液和C液混合均匀后放入4℃冰箱中陈化形成水凝胶,再将水凝胶放入超纯水中浸泡1~4 h并重复2~4次后封装水凝胶,用Co60 照射灭菌,即获得烧烫伤创面修复的双交联抗菌水凝胶。
上述步骤(1)中,硝酸锌和2-甲基咪唑的物质的量之比为 1:(5~10),硝酸锌与聚六亚甲基双胍的质量之比为1:(0.01~2)。
上述步骤(2)中,所述类人胶原蛋白的分子量为70000~110000Da,类人胶原蛋白与EDC和NHS的质量之比为:(0.5~5):1:1,类人胶原蛋白和3-氨基苯硼酸半硫酸盐的质量之比为1:(0.5~2)。
上述步骤(3)中,负载聚六亚甲基双胍的ZIF-8纳米粒子与改性的类人胶原蛋白、海藻酸钠的质量之比为(0.05~0.4):(5~30):1,海藻酸钠与EDC和NHS的质量之比为(0.5~5):1:1。
上述步骤(3)中,所述的A液的固液比g/ml为0.5~3 %,B液的固液比g/ml为5~30%,C液的固液比g/ml为0.5~4%。
本发明采用具有良好生物相容性和促上皮细胞生长的类人胶原蛋白接枝3-氨基苯硼酸改性,再通过1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和N-羟基琥珀酰亚胺(NHS)对改性后的类人胶原蛋白和海藻酸钠分别活化。在活化剂的存在下,将活化的改性类人胶原蛋白和海藻酸钠混合后,蛋白分子上的氨基与海藻酸钠分子会形成分子间的酰胺键,蛋白分子上接枝的3-氨基苯硼酸上的苯硼酸键与海藻酸钠分子的羟基会形成苯硼酸酯键,两种分子间键相互交织形成网络立体结构。其中,在构筑水凝胶中负载聚六亚甲基双胍内置的ZIF-8纳米粒子,进一步功能化了水凝胶具有良好的缓释抗菌功效。
本发明制备的双交联抗菌水凝胶,具有良好的生物相容性、抗菌性、表皮粘附性,且因为苯硼酸酯键的存在具有良好的pH响应性,能因烧烫伤创面炎症的pH变化而响应性水解,释放出负载聚六亚甲基双胍内置的ZIF-8纳米粒子强化水凝胶的抑菌性能,有效起到创面组织的消炎效果。本发明的制备方法简单易行,重现性好,制备的双交联抗菌水凝胶兼具长效缓释抗菌能力和良好的促上皮细胞生长能力,在烧烫伤创面修复方面具有理想的性能,应用前景广阔。
附图说明
图1为本发明实施例1中制备的负载聚六亚甲基双胍的ZIF-8纳米粒子的SEM图;
图2为本发明实施例1中制备的负载聚六亚甲基双胍的ZIF-8纳米粒子的XRD图;
图3为本发明实施例1中制备的负载聚六亚甲基双胍的ZIF-8纳米粒子的UV-Vis图;
图4为本发明实施例1中制备的改性胶原蛋白的核磁共振波谱NMR图;
图5为本发明实施例1制备的用于烧烫伤创面修复的双交联抗菌水凝胶粘附情况的示意图;
图6为本发明实施例4中的细胞毒性实验结果图;
图7为本发明实施例4中的抑菌实验结果图。
实施方式
实施例1
步骤一、负载聚六亚甲基双胍的ZIF-8纳米粒子的制备
将0.02g聚六亚甲基双胍和0.66g 2-甲基咪唑溶解于50ml甲醇中,再向其中加入0.30g硝酸锌六水合物,室温下搅拌24 h后,离心收集沉淀,将沉淀用乙醇洗涤3次后放于真空干燥箱中干燥12 h,获得负载聚六亚甲基双胍的ZIF-8纳米粒子。图1为ZIF-8纳米粒子的SEM图,表明制备的样品为直径400nm的菱形十二面体。图2为ZIF-8纳米粒子的XRD检测结果图,表明负载聚六亚甲基双胍与否未改变ZIF-8纳米粒子的晶体结构。图3的UV-Vis图表明聚六亚甲基双胍负载到了ZIF-8纳米粒子中。
步骤二、改性的类人胶原蛋白(HLC)的制备
在磁力搅拌下,将2.50g的类人胶原蛋白溶解于150ml中性PBS缓冲液中,依次向其中加入1.50g的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和1.50g的N-羟基琥珀酰亚胺(NHS),再向其中加入1.50g的3-氨基苯硼酸半硫酸盐(APBA),并调节溶液pH为4.5的状态下搅拌12 h后,将反应混合液装入透析袋(透析袋截留分子量为3500)用蒸馏水连续透析3天,收集透析母液进行冷冻干燥后,将干燥后获得改性的类人胶原蛋白。图4为改性的胶原蛋白的核磁共振波谱NMR图,表明经过改性,3-氨基苯硼酸半硫酸盐成功被接枝到类人胶原蛋白分子上。
步骤三、双交联抗菌水凝胶的制备
将0.1g负载聚六亚甲基双胍的ZIF-8纳米粒子溶于10ml超纯水中制成A液;将12g改性的类人胶原蛋白溶于60ml中性PBS缓冲液中制成B液;将0.6g海藻酸钠溶解于30ml超纯水中,向其中加入EDC和NHS并搅拌溶解制成C液。将A液、B液和C液混合均匀后分装于模具中,放入4℃冰箱中陈化12h形成水凝胶,再将水凝胶放入超纯水中浸泡2 h并重复3次后,封装水凝胶,用Co60 照射灭菌,即获得烧烫伤创面修复的双交联抗菌水凝胶。对该双交联抗菌水凝胶进行皮肤粘附实验,结果如图5所示,表明该双交联抗菌水凝胶具有良好的表皮粘附性,可有效贴附于表皮上。
实施例2
步骤一、负载聚六亚甲基双胍的ZIF-8纳米粒子的制备:
将0.1g聚六亚甲基双胍和3g 2-甲基咪唑溶解于500ml甲醇中,再向其中加入1.5g硝酸锌六水合物,室温下搅拌12 h后,离心收集沉淀,将沉淀用乙醇洗涤3次后放于真空干燥箱中干燥12 h,获得负载聚六亚甲基双胍的ZIF-8纳米粒子;
步骤二、改性的类人胶原蛋白(HLC)的制备:
在磁力搅拌下,将5g的类人胶原蛋白溶解于200ml中性PBS缓冲液中,依次向其中加入3g的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和3g的N-羟基琥珀酰亚胺(NHS),再向其中加入5g的3-氨基苯硼酸半硫酸盐(APBA),并调节溶液pH为4.5的状态下搅拌12 h后,将反应混合液装入透析袋(透析袋截留分子量为3500)用蒸馏水连续透析3天,收集透析母液进行冷冻干燥后,将干燥后获得改性的类人胶原蛋白。
步骤三、双交联抗菌水凝胶的制备
将0.2g负载聚六亚甲基双胍的ZIF-8纳米粒子溶于10ml超纯水中制成A液;将20g改性的类人胶原蛋白溶于100ml中性PBS缓冲液中制成B液;将2g海藻酸钠溶解于60ml超纯水中,向其中加入EDC和NHS并搅拌溶解制成C液。将A液、B液和C液混合均匀后分装于模具中,放入4℃冰箱中陈化12h形成水凝胶,再将水凝胶放入超纯水中浸泡2h并重复3次后,封装水凝胶,用Co60 照射灭菌,即获得烧烫伤创面修复的双交联抗菌水凝胶。
实施例3
步骤一、负载聚六亚甲基双胍的ZIF-8纳米粒子的制备:
将0.2g聚六亚甲基双胍和7g 2-甲基咪唑溶解于500ml甲醇中,再向其中加入3g硝酸锌六水合物,室温下搅拌24 h后,离心收集沉淀,将沉淀用乙醇洗涤3次后放于真空干燥箱中干燥12 h,获得负载聚六亚甲基双胍的ZIF-8纳米粒子;
步骤二、改性的类人胶原蛋白(HLC)的制备:
在磁力搅拌下,将5g的类人胶原蛋白溶解于200ml中性PBS缓冲液中,依次向其中加入3g的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和3g的N-羟基琥珀酰亚胺(NHS),再向其中加入5g的3-氨基苯硼酸半硫酸盐(APBA),并调节溶液pH为5的状态下搅拌6h后,将反应混合液装入透析袋(透析袋截留分子量为3500)用蒸馏水连续透析3天,收集透析母液进行冷冻干燥后,将干燥后获得改性的类人胶原蛋白。
步骤三、双交联抗菌水凝胶的制备
将0.2g负载聚六亚甲基双胍的ZIF-8纳米粒子溶于10ml超纯水中制成A液;将20g改性的类人胶原蛋白溶于100ml中性PBS缓冲液中制成B液;将2g海藻酸钠溶解于60ml超纯水中,向其中加入EDC和NHS并搅拌溶解制成C液。将A液、B液和C液混合均匀后分装于模具中,放入4℃冰箱中陈化24h形成水凝胶,再将水凝胶放入超纯水中浸泡4h并重复3次后,封装水凝胶,用Co60 照射灭菌,即获得烧烫伤创面修复的双交联抗菌水凝胶。
实施例4 双交联抗菌水凝胶的细胞学实验
本实施例采用实施例1中获得烧烫伤创面修复的双交联抗菌水凝胶为研究对象,考察其生物学相容性。
将实验采用实施例1中的含负载聚六亚甲基双胍的ZIF-8纳米粒子的抗菌水凝胶(样品2)冷冻干燥,并使用Co60照射灭菌,放进不同的50mL无菌离心管中,以0.1g/mL的用量向其中加入1640培养液后,放置于37℃的含有5% CO2的无菌培养箱中培养3天,得到水凝胶浸提液。
将L929细胞在96孔板中培养24h,使细胞贴壁。吸出原有1640培养液,换上水凝胶浸提液培养24、48、72h,对照组为1640培养液。细胞培养相应时间后,在每个孔中加入50μL的MTT,放置2h~4h后,吸去孔中所有溶液,加入150μL的DMSO,于490nm下在酶标仪中测定吸光度,得到的吸光度值,结果如图6所示,表明加了负载聚六亚甲基双胍的ZIF-8纳米粒子的水凝胶(样品2)的细胞存活率均高于80%,表明实施例1中的双交联抗菌水凝胶具有良好的生物相容性,可用于生物体。
实施例5 双交联抗菌水凝胶的抑菌实验
本实施例是采用实施例1中获得烧烫伤创面修复的双交联抗菌水凝胶为研究对象,考察其抑菌性能。
(1)不添加负载聚六亚甲基双胍的ZIF-8纳米粒子的水凝胶的制备
将14g改性的类人胶原蛋白溶于70ml中性PBS缓冲液中制成B液;将0.6g海藻酸钠溶解于30ml超纯水中,向其中加入EDC和NHS并搅拌溶解制成C液。将B液和C液混合均匀后分装于模具中,放入4℃冰箱中陈化12h形成水凝胶,再将水凝胶放入超纯水中浸泡2 h并重复2次后,封装水凝胶,用Co60 照射灭菌,即获得不添加负载聚六亚甲基双胍的ZIF-8纳米粒子的水凝胶(标记为:样品1)。
(2)双交联抗菌水凝胶的抑菌实验
实施例1中获得烧烫伤创面修复的双交联抗菌水凝胶标记为样品2,实验采用抑菌圈法,对照组选取样品1,实验菌选用大肠杆菌和金黄色葡萄球菌。
将待测凝胶样品1和2分别置于均匀涂满细菌悬浮液(大肠杆菌和金黄色葡萄球菌)的琼脂培养基上,24h 观察细菌生长情况并拍照(图 7),根据图 7所示,样品1对应的培养皿上布满了菌体,而样品2上无菌体出现,说明负载聚六亚甲基双胍的ZIF-8纳米粒子的水凝胶具有很强的抑菌能力,抑制和杀灭了大肠杆菌和金黄色葡萄球菌的生长。
最后应当说明的是,尽管结合实施例对本发明做了以上描述,但本发明并不局限于上述实施例及应用领域,上述方案仅仅做示意及指导用途,而不是限制性的。本领域普通技术人员在本说明书的启发下和在不脱离本发明权力要求所保护的范围的情况下,对以上实施例所作的任何简单修改、变更以及等效结构变化,均仍属于本发明技术方案的保护范围内。
Claims (5)
1.一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,其特征在于包括如下步骤:
(1)负载聚六亚甲基双胍的ZIF-8 纳米粒子的制备将聚六亚甲基双胍和2-甲基咪唑溶解于甲醇中,向其中加入硝酸锌,室温充分反应后离心收集沉淀,用乙醇洗涤、干燥获得负载聚六亚甲基双胍的ZIF-8 纳米粒子;
(2)改性的类人胶原蛋白的制备
将类人胶原蛋白溶解于中性PBS 缓冲液中,向其中加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺,再加入3-氨基苯硼酸半硫酸盐,调节溶液pH 为4~5并进行充分搅拌,将混合液置于截留分子量为3500的透析袋进行透析2-5 天,收集透析母液并冷冻干燥获得改性的类人胶原蛋白;
(3)双交联抗菌水凝胶的制备
将负载聚六亚甲基双胍的ZIF-8 纳米粒子溶于超纯水中制成A 液,将改性的类人胶原蛋白溶于中性PBS 缓冲液中制成B 液,将海藻酸钠溶解于超纯水中,向其中加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺并搅拌溶解制成C 液;将A 液、B液和C液混合均匀后放入4°C 冰箱中陈化形成水凝胶,再将水凝胶放入超纯水中浸泡1~4 h并重复2~4 次后封装水凝胶,用Co60 照射灭菌,即获得烧烫伤创面修复的双交联抗菌水凝胶;
所述负载聚六亚甲基双胍的ZIF-8 纳米粒子与改性的类人胶原蛋白、海藻酸钠的质量之比为(0.05~0.4):(5~30):1。
2.根据权利要求1 所述的用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,其特征在于:步骤(1)中,硝酸锌和2-甲基咪唑的物质的量之比为 1:(5~10),硝酸锌与聚六亚甲基双胍的质量之比为1:(0.01~2)。
3.根据权利要求1 所述的用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,其特征在于:步骤(2)中,所述类人胶原蛋白的分子量为70000~110000 Da,类人胶原蛋白与1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺的质量之比为:(0.5~5):1:1,类人胶原蛋白和3-氨基苯硼酸半硫酸盐的质量之比为1:(0.5~2)。
4.根据权利要求1 所述的用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,其特征在于:步骤(3)中,海藻酸钠与EDC 和NHS 的质量之比为(0.5~5):1:1。
5.根据权利要求1 所述的用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法,其特征在于:步骤(3)中,所述的A 液的固液比g/ml 为0.5~3 %,B 液的固液比g/ml 为5~30%,C液的固液比g/ml 为0.5~4%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111065439.9A CN113999410B (zh) | 2021-09-13 | 2021-09-13 | 一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111065439.9A CN113999410B (zh) | 2021-09-13 | 2021-09-13 | 一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113999410A CN113999410A (zh) | 2022-02-01 |
CN113999410B true CN113999410B (zh) | 2024-01-19 |
Family
ID=79921327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111065439.9A Active CN113999410B (zh) | 2021-09-13 | 2021-09-13 | 一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113999410B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115068684A (zh) * | 2022-06-30 | 2022-09-20 | 华南理工大学 | 用于糖尿病慢性创面修复的载姜黄素水凝胶及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014074503A1 (en) * | 2012-11-06 | 2014-05-15 | Imbed Biosciences, Inc. | Methods and compositions for wound healing |
CN104941332A (zh) * | 2015-06-03 | 2015-09-30 | 中国科学院理化技术研究所 | 一种抗菌、除菌、防霾性能良好的空气过滤器的制备方法 |
CN105664234A (zh) * | 2016-02-03 | 2016-06-15 | 西北大学 | 一种抗菌性类人胶原蛋白创面医护膜敷料 |
CN108530651A (zh) * | 2018-01-25 | 2018-09-14 | 四川大学 | pH敏感、可自愈、可细胞黏附医用水凝胶及其制备方法 |
CN109705573A (zh) * | 2017-10-26 | 2019-05-03 | 中国石油化工股份有限公司 | 一种胍盐复合抗菌剂及其制备方法 |
CN109706533A (zh) * | 2017-10-26 | 2019-05-03 | 中国石油化工股份有限公司 | 一种抗菌防霉丙纶长丝及其制备方法 |
CN109943976A (zh) * | 2019-04-25 | 2019-06-28 | 中国科学院长春应用化学研究所 | 一种多功能静电纺丝纤维敷料及其制备方法 |
CN112717200A (zh) * | 2021-01-13 | 2021-04-30 | 常州市中辉医疗器械有限公司 | 一种重组人胶原蛋白可吸收水凝胶皮肤支架及其制备方法、使用方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2934158T3 (es) * | 2015-04-28 | 2023-02-17 | Frank Dicosmo | Biomateriales de colágeno bioactivo y métodos para su fabricación |
-
2021
- 2021-09-13 CN CN202111065439.9A patent/CN113999410B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014074503A1 (en) * | 2012-11-06 | 2014-05-15 | Imbed Biosciences, Inc. | Methods and compositions for wound healing |
CN104941332A (zh) * | 2015-06-03 | 2015-09-30 | 中国科学院理化技术研究所 | 一种抗菌、除菌、防霾性能良好的空气过滤器的制备方法 |
CN105664234A (zh) * | 2016-02-03 | 2016-06-15 | 西北大学 | 一种抗菌性类人胶原蛋白创面医护膜敷料 |
CN109705573A (zh) * | 2017-10-26 | 2019-05-03 | 中国石油化工股份有限公司 | 一种胍盐复合抗菌剂及其制备方法 |
CN109706533A (zh) * | 2017-10-26 | 2019-05-03 | 中国石油化工股份有限公司 | 一种抗菌防霉丙纶长丝及其制备方法 |
CN108530651A (zh) * | 2018-01-25 | 2018-09-14 | 四川大学 | pH敏感、可自愈、可细胞黏附医用水凝胶及其制备方法 |
CN109943976A (zh) * | 2019-04-25 | 2019-06-28 | 中国科学院长春应用化学研究所 | 一种多功能静电纺丝纤维敷料及其制备方法 |
CN112717200A (zh) * | 2021-01-13 | 2021-04-30 | 常州市中辉医疗器械有限公司 | 一种重组人胶原蛋白可吸收水凝胶皮肤支架及其制备方法、使用方法 |
Non-Patent Citations (3)
Title |
---|
3-氨基苯硼酸为功能单体在壳聚糖上印迹牛血清白蛋白的研究;王华芳等;高等学校化学学报;第29卷(第4期);726-730 * |
Fabrication of collagen with polyhexamethylene biguanide: A potential scaffold for infected wounds;Sripriya Ramasamy et al;Journal of biomedical materials research;第110卷(第3期);535-546 * |
用于烧烫伤感染创面修复的双交联抑菌水凝胶的制备及性能研究;李娜;中国优秀硕士学位论文全文数据库工程科技Ⅰ辑(第2期);B016-3423 * |
Also Published As
Publication number | Publication date |
---|---|
CN113999410A (zh) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Amirian et al. | In-situ crosslinked hydrogel based on amidated pectin/oxidized chitosan as potential wound dressing for skin repairing | |
CN113577377B (zh) | 一种活性氧消除抗菌消炎水凝胶皮肤敷料及其制备方法 | |
JP4214051B2 (ja) | エラスチン架橋体およびその製造方法 | |
CN111019162A (zh) | 以氧化透明质酸为交联剂的壳聚糖多肽衍生物自交联水凝胶的制备方法及应用 | |
CN112300420A (zh) | 一种可注射抗菌互穿双网络水凝胶及其制备方法和应用 | |
JP3955107B2 (ja) | 架橋多糖の製造法 | |
CN113817181B (zh) | 一种碳量子点修饰的双网络水凝胶及其制备方法 | |
CN110152055B (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
CN114796620B (zh) | 一种用作医用植入材料的互穿网络水凝胶及其制备方法和应用 | |
CN107823699B (zh) | 止血防粘连膜及其制备方法 | |
CN113999410B (zh) | 一种用于烧烫伤创面修复的双交联抗菌水凝胶的制备方法 | |
CN114392388A (zh) | 一种水凝胶组合物及其应用 | |
CN115487337A (zh) | 一种皮肤修复用敷料贴及其制备方法 | |
Cao et al. | Preparation of biodegradable carboxymethyl cellulose/dopamine/Ag NPs cryogel for rapid hemostasis and bacteria-infected wound repair | |
CN115850733B (zh) | 一种可注射用纳米粘土水凝胶及其制备方法和应用 | |
CN114479124B (zh) | 一种可自愈水凝胶、其制备方法及应用 | |
CN111234163B (zh) | 一种兼具抗菌修复性能的纳米凝胶及其制备方法与应用 | |
CN114478831A (zh) | 一种新型高分子材料及其制备方法与应用 | |
CN113616805A (zh) | 一种壳聚糖水凝胶及其制备方法和应用 | |
CN114702704A (zh) | 一种基于单向纳米孔脱水的功能性高分子膜/水凝胶膜、制备方法及装置 | |
CN112057667A (zh) | 一种可降解吸收的生物止血材料 | |
US10059809B2 (en) | Material and preparation of biocompatible hemostatic water soluble chitosan | |
CN115626982B (zh) | 一种氮氧自由基修饰的赖氨酸基聚酯酰胺聚合物及其制备方法与应用 | |
CN114832142B (zh) | 一种壳聚糖复合敷料及其制备方法 | |
CN114796597B (zh) | 一种鞘氨醇基水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |